These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 11106152)

  • 1. A case of paroxetine-induced dyskinetic movements.
    Lee MS; Nam JW
    J Clin Psychopharmacol; 2000 Dec; 20(6):712-3. PubMed ID: 11106152
    [No Abstract]   [Full Text] [Related]  

  • 2. Effect of nortriptyline and paroxetine on extrapyramidal signs and symptoms: A prospective double-blind study in depressed elderly patients.
    Mamo DC; Sweet RA; Mulsant BH; Pollock BG; Miller MD; Stack JA; Begley AE; Reynolds CF
    Am J Geriatr Psychiatry; 2000; 8(3):226-31. PubMed ID: 10910421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paroxetine in adolescent major depression.
    Parsons M
    J Am Acad Child Adolesc Psychiatry; 2002 Apr; 41(4):364; author reply 364. PubMed ID: 11931589
    [No Abstract]   [Full Text] [Related]  

  • 4. Paroxetine in adolescent major depression.
    Weintrob A
    J Am Acad Child Adolesc Psychiatry; 2002 Apr; 41(4):363-4; author reply 364. PubMed ID: 11931587
    [No Abstract]   [Full Text] [Related]  

  • 5. Paroxetine in the treatment of adolescent major depression.
    Correll CU; Pleak RR
    J Am Acad Child Adolesc Psychiatry; 2002 Nov; 41(11):1269; author reply 1270. PubMed ID: 12410065
    [No Abstract]   [Full Text] [Related]  

  • 6. Paroxetine in the treatment of adolescent major depression.
    Silveira R; Jainer AK; Singh R
    J Am Acad Child Adolesc Psychiatry; 2002 Nov; 41(11):1270; author reply 1271. PubMed ID: 12410066
    [No Abstract]   [Full Text] [Related]  

  • 7. Brain damage and tardive dyskinesia.
    al-Adwani A
    Br J Psychiatry; 1995 Sep; 167(3):410-1. PubMed ID: 7496660
    [No Abstract]   [Full Text] [Related]  

  • 8. DRD3, but not BDNF, genotype affects treatment response to paroxetine in major depressive disorder: a preliminary study.
    Tsuchimine S; Yasui-Furukori N; Nakagami T; Sato Y; Kaneko S
    J Clin Psychopharmacol; 2012 Oct; 32(5):724-6. PubMed ID: 22926616
    [No Abstract]   [Full Text] [Related]  

  • 9. Effects of prolonged selective serotonin reuptake inhibition on the development and expression of L-DOPA-induced dyskinesia in hemi-parkinsonian rats.
    Conti MM; Ostock CY; Lindenbach D; Goldenberg AA; Kampton E; Dell'isola R; Katzman AC; Bishop C
    Neuropharmacology; 2014 Feb; 77():1-8. PubMed ID: 24067924
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SSRI-induced enuresis: a case report.
    Monji A; Yanagimoto K; Yoshida I; Hashioka S
    J Clin Psychopharmacol; 2004 Oct; 24(5):564-5. PubMed ID: 15349022
    [No Abstract]   [Full Text] [Related]  

  • 11. Switching Selective Serotonin Reuptake Inhibitors in Adolescents with Selective Serotonin Reuptake Inhibitor-Resistant Major Depressive Disorder: Balancing Tolerability and Efficacy.
    Strawn JR; Mills JA; Croarkin PE
    J Child Adolesc Psychopharmacol; 2019 May; 29(4):250-255. PubMed ID: 30810350
    [No Abstract]   [Full Text] [Related]  

  • 12. Delirium associated with paroxetine in an elderly depressive patient: a case report.
    Wakeno M; Okugawa G; Takekita Y; Kato M; Fukuda T; Yamashita M; Hosoi Y; Azuma J; Kinoshita T
    Pharmacopsychiatry; 2007 Sep; 40(5):199-200. PubMed ID: 17874351
    [No Abstract]   [Full Text] [Related]  

  • 13. Nonadherence to paroxetine: a study based on monitoring plasma paroxetine levels.
    Yoshimura R; Ikenouchi-Sugita A; Umene-Nakano W; Hori H; Ueda N; Nakamura J
    J Clin Psychopharmacol; 2010 Feb; 30(1):82-3. PubMed ID: 20075657
    [No Abstract]   [Full Text] [Related]  

  • 14. Serotonin transporter inhibition attenuates l-DOPA-induced dyskinesia without compromising l-DOPA efficacy in hemi-parkinsonian rats.
    Bishop C; George JA; Buchta W; Goldenberg AA; Mohamed M; Dickinson SO; Eissa S; Eskow Jaunarajs KL
    Eur J Neurosci; 2012 Sep; 36(6):2839-48. PubMed ID: 22762478
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient.
    Hébant B; Guillaume M; Desbordes M; Gaillon G; Maltête D; Lefaucheur R
    Rev Neurol (Paris); 2016 Dec; 172(12):788-789. PubMed ID: 27838092
    [No Abstract]   [Full Text] [Related]  

  • 16. Paroxetine and tardive dyskinesia.
    Botsaris SD; Sypek JM
    J Clin Psychopharmacol; 1996 Jun; 16(3):258-9. PubMed ID: 8784663
    [No Abstract]   [Full Text] [Related]  

  • 17. When Discontinuing SSRI Antidepressants Is a Challenge: Management Tips.
    Jha MK; Rush AJ; Trivedi MH
    Am J Psychiatry; 2018 Dec; 175(12):1176-1184. PubMed ID: 30501420
    [No Abstract]   [Full Text] [Related]  

  • 18. Psychopharmacological treatment of major depressive disorder in children and adolescents.
    Varley CK
    JAMA; 2003 Aug; 290(8):1091-3. PubMed ID: 12941683
    [No Abstract]   [Full Text] [Related]  

  • 19. Positional asphyxiation from paroxetine.
    Malik A; Ravasia S
    Am J Psychiatry; 2005 Jun; 162(6):1225-6. PubMed ID: 15930078
    [No Abstract]   [Full Text] [Related]  

  • 20. Personalizing the care of geriatric depression.
    Alexopoulos GS
    Am J Psychiatry; 2008 Jul; 165(7):790-2. PubMed ID: 18593780
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.